Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 17, 2016

Primary Completion Date

November 14, 2019

Study Completion Date

November 14, 2019

Conditions
Sickle Cell Disease
Interventions
PROCEDURE

micro- and macro-circulatory vascular remodelling measures not practice in routine care

Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity

PROCEDURE

Biological measures not practice in routine care

Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1

Trial Locations (1)

93009

Hôpital Avicenne, Bobigny

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theravia

INDUSTRY

NCT02721472 - Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter